Supplementary Figure 3 from Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions

Supplementary Figure 3: Forest Plot of Hazard Ratio of Treatment Effect on Progression-Free Survival, According to Baseline Prognostic Factors. (A) Intent-to-treat population, n=701; (B) Subset: Solitary lesion (BCLC A) and RFA dwell time {greater than or equal to}45 min, n=285.